NASDAQ:ELOX - Eloxx Pharmaceuticals Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $4.50
  • Forecasted Upside: 116.35 %
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$2.08
+0.30 (1.20%)
1 month | 3 months | 12 months
Get New Eloxx Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ELOX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ELOX

Average Price Target: $4.50
▲ +116.35% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Eloxx Pharmaceuticals in the last 3 months. The average price target is $4.50, with a high forecast of $5.00 and a low forecast of $4.00. The average price target represents a 116.35% upside from the last price of $2.08.

Buy

The current consensus among 3 polled investment analysts is to buy stock in Eloxx Pharmaceuticals. This rating changed within the last month from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/26/2019
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
3/25/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
6/23/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
9/21/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
12/20/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
3/20/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
5/19/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/18/2021

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/27/2021B. RileyInitiated CoverageBuy$5.00Low
5/19/2021Piper SandlerLower Price TargetOverweight$6.00 ➝ $4.00Low
11/9/2020HC WainwrightReiterated RatingNeutralHigh
6/10/2020CitigroupDowngradeBuy ➝ Neutral$11.00 ➝ $4.00High
5/12/2020Canaccord GenuityReiterated RatingBuy$6.00High
5/8/2020Janney Montgomery ScottLower Price TargetBuy$13.00 ➝ $10.00High
5/8/2020Piper SandlerLower Price TargetOverweight$10.00 ➝ $6.00High
3/9/2020CitigroupLower Price TargetNeutral$31.00 ➝ $11.00High
3/6/2020Janney Montgomery ScottLower Price TargetBuy$14.00 ➝ $13.00N/A
3/6/2020Piper SandlerLower Price Target$14.00 ➝ $10.00N/A
3/6/2020HC WainwrightReiterated RatingNeutral$10.00 ➝ $3.00High
9/6/2019Janney Montgomery ScottInitiated CoverageBuy$14.00Low
8/8/2019SunTrust BanksLower Price TargetBuy$10.00Medium
5/15/2019Canaccord GenuityReiterated RatingBuy$20.00 ➝ $17.00Low
12/24/2018HC WainwrightReiterated RatingNeutralLow
12/24/2018HC WainwrightInitiated CoverageNeutral ➝ Neutral$10.00Low
7/3/2018CitigroupInitiated CoverageBuy$31.00Low
6/29/2018Canaccord GenuityInitiated CoverageBuy$24.00High
6/25/2018SunTrust BanksInitiated CoverageBuy$26.00Medium
5/1/2018Piper Jaffray CompaniesInitiated CoverageOverweight$20.00Medium
(Data available from 6/18/2016 forward)
Eloxx Pharmaceuticals logo
Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing ribonucleic acid modulating drug candidates for the treatment of rare and ultra-rare premature stop codon diseases. Its lead investigational drug product candidate is ELX-02, which is in Phase 2 clinical trial that focuses on the treatment of cystic fibrosis and nephropathic cystinosis patients with diagnosed nonsense mutations. The company was incorporated in 2013 and is headquartered in Waltham, Massachusetts.
Read More

Today's Range

Now: $2.08
Low: $1.98
High: $2.18

50 Day Range

MA: $1.96
Low: $1.35
High: $2.76

52 Week Range

Now: $2.08
Low: $1.34
High: $6.77

Volume

2,998,026 shs

Average Volume

940,501 shs

Market Capitalization

$99.54 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.48

Frequently Asked Questions

What sell-side analysts currently cover shares of Eloxx Pharmaceuticals?

The following Wall Street research analysts have issued research reports on Eloxx Pharmaceuticals in the last year: B. Riley, HC Wainwright, Piper Sandler, and Zacks Investment Research.
View the latest analyst ratings for ELOX.

What is the current price target for Eloxx Pharmaceuticals?

2 Wall Street analysts have set twelve-month price targets for Eloxx Pharmaceuticals in the last year. Their average twelve-month price target is $4.50, suggesting a possible upside of 113.3%. B. Riley has the highest price target set, predicting ELOX will reach $5.00 in the next twelve months. Piper Sandler has the lowest price target set, forecasting a price of $4.00 for Eloxx Pharmaceuticals in the next year.
View the latest price targets for ELOX.

What is the current consensus analyst rating for Eloxx Pharmaceuticals?

Eloxx Pharmaceuticals currently has 1 hold rating and 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ELOX will outperform the market and that investors should add to their positions of Eloxx Pharmaceuticals.
View the latest ratings for ELOX.

What other companies compete with Eloxx Pharmaceuticals?

How do I contact Eloxx Pharmaceuticals' investor relations team?

Eloxx Pharmaceuticals' physical mailing address is 950 WINTER STREET, WALTHAM MA, 02451. The company's listed phone number is 781 577 5300 and its investor relations email address is [email protected] The official website for Eloxx Pharmaceuticals is www.eloxxpharma.com.